LegalizeCommission Delegated Regulation (EU) 2024/2564 of 19 June 2024 amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council as regards the harmonised classification and labelling of certain substances
This is the act as published. Later amendments are not folded into the text below: each one is a separate act in this repository and an entry in this law's history.
| Image omitted; see official source | Official Journal of the European Union | EN L series |
| --- | --- | --- |
| 2024/2564 | 30.9.2024 |
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 [^ntr1-L_202402564EN.000101-E0001], and in particular Article 37(5) thereof,
Whereas:
- (1) Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.
- (2) Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (‘the Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment (RAC) of the Agency adopted, after having taken account of the comments received from the parties concerned, the following opinions [^ntr2-L_202402564EN.000101-E0002] on those proposals:
- — Opinion of 18 March 2022 concerning multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T;
- — Opinion of 18 March 2022 concerning α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde;
(2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3];
- — Opinion of 18 March 2022 concerning acetone oxime;
- — Opinion of 18 March 2022 concerning (3E)-dec-3-en-2-one;
- — Opinion of 18 March 2022 concerning 2,3-epoxypropyl neodecanoate;
- — Opinion of 18 March 2022 concerning propyl 3,4,5-trihydroxybenzoate;
- — Opinion of 18 March 2022 concerning benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate;
- — Opinion of 18 March 2022 concerning hexyl salicylate;
- — Opinion of 18 March 2022 concerning sulfur;
- — Opinion of 18 March 2022 concerning reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2];
- — Opinion of 18 March 2022 concerning 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol;
- — Opinion of 30 May 2022 concerning glyphosate (ISO); N-(phosphonomethyl)glycine;
- — Opinion of 2 June 2022 concerning silver massive: [particle diameter ≥ 1 mm];
- — Opinion of 2 June 2022 concerning silver powder: [particle diameter > 100 nm < 1 mm];
- — Opinion of 2 June 2022 concerning silver nano: [particle diameter > 1 nm ≤ 100 nm];
- — Opinion of 2 June 2022 concerning S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (R a S a)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide];
- — Opinion of 2 June 2022 concerning 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one;
- — Opinion of 2 June 2022 concerning formaldehyde … %;
- — Opinion of 2 June 2022 concerning formic acid … %;
- — Opinion of 2 June 2022 concerning dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid;
- — Opinion of 2 June 2022 concerning 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate;
- — Opinion of 2 June 2022 concerning peracetic acid … %;
- — Opinion of 2 June 2022 concerning tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy) ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotised 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3];
- — Opinion of 15 September 2022 concerning perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5];
- — Opinion of 15 September 2022 concerning perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4]
- — Opinion of 15 September 2022 concerning sodium peroxometaborate;
- — Opinion of 15 September 2022 concerning trimethyl borate;
- — Opinion of 15 September 2022 concerning ethanethiol;
ethyl mercaptan;
- — Opinion of 15 September 2022 concerning 1H-benzotriazole;
- — Opinion of 15 September 2022 concerning methyl-1H-benzotriazole;
- — Opinion of 15 September 2022 concerning N,N'-methylenediacrylamide;
- — Opinion of 15 September 2022 concerning Sodium 3-(allyloxy)-2-hydroxypropanesulphonate;
- — Opinion of 1 December 2022 concerning tert-butyl 2-ethylperoxyhexanoate;
- — Opinion of 1 December 2022 concerning n-hexane;
- — Opinion of 1 December 2022 concerning biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl;
- — Opinion of 1 December 2022 concerning copper [specific surface area > 0,67 mm2/mg];
- — Opinion of 1 December 2022 concerning reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol;
- — Opinion of 1 December 2022 concerning 1,4-dichloro-2-nitrobenzene;
- — Opinion of 1 December 2022 concerning 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16];
- — Opinion of 1 December 2022 concerning pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate;
- — Opinion of 1 December 2022 concerning dibenzoyl peroxide; benzoyl peroxide;
- — Opinion of 1 December 2022 concerning fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine.
- (3) The Commission has received additional information from stakeholders contesting the scientific assessment set out in the RAC opinions of 18 March 2022 concerning benthiavalicarb-isopropyl, 2,3-epoxypropyl neodecanoate, multi-walled carbon tubes, hexyl salicylate, in the RAC opinions of 2 June 2022 concerning silver massive, silver powder and silver nano and in the RAC opinions of 1 December 2022 concerning n-hexane and copper. The additional information has been assessed by the Commission and has not been found sufficient to cast doubts on the scientific analysis contained in the RAC opinions.
- (4) With regard to the substance copper flakes (coated with aliphatic acid) (index number 029-019-01-X [^ntr3-L_202402564EN.000101-E0003]), its entry for its classification as hazardous for the aquatic environment should be amended to be in accordance with the more generic entry copper [specific surface area > 0,67 mm2/mg] (index number 029-026-00-0), inserted in the Annex.
- (5) With regard to the substance granulated copper [^ntr4-L_202402564EN.000101-E0004] (index number 029-024-00-X), its entry should be deleted as it is covered by the more generic entry copper [specific surface area > 0,67 mm2/mg] (index number 029-026-00-0), inserted in the Annex.
- (6) Acute Toxicity Estimates (ATE) are mainly used to determine the classification for human health acute toxicity of mixtures containing substances classified for acute toxicity. The inclusion of harmonised ATE values in the entries listed in Annex VI to Regulation (EC) No 1272/2008 facilitates the harmonisation of the classification of mixtures and provides support for enforcement authorities. Following further scientific assessment, an ATE value for the inhalation route has been derived for fenpropidin (index number 612-299-00-0), in addition to those proposed in the RAC opinions for other substances. That ATE value should be inserted in the penultimate column of Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008.
- (7) The entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 have been replaced by the entries for perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5] (index number 005-022-00-4), for perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] (index number 005-023-00-X) and for sodium peroxometaborate (index number 005-024-00-5) and should therefore be deleted.
- (8) In light of the RAC opinions, it is appropriate to introduce, update or delete the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions and following the further assessments.
- (9) Regulation (EC) No 1272/2008 should therefore be amended accordingly.
- (10) Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,
HAS ADOPTED THIS REGULATION:
Article 1
Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.
Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 1 May 2026 However, substances and mixtures may be classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 as amended by this Regulation from the date of entry into force of this Regulation.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 19 June 2024.
For the Commission
The President
Ursula VON DER LEYEN
[^ntr1-L_202402564EN.000101-E0001]: OJ L 353, 31.12.2008, p. 1, ELI: http://data.europa.eu/eli/reg/2008/1272/oj.
[^ntr2-L_202402564EN.000101-E0002]: The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/.
[^ntr3-L_202402564EN.000101-E0003]: See RAC Opinion of 1 December 2022 concerning copper [specific surface area > 0,67 mm2/mg], listed above;
ANNEX
Part 3, Table 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:
- (1) the following entries are inserted following the consecutive order of the index numbers corresponding to each entry:
| Index No | Chemical Name | EC No | CAS No | Classification | Classification | Labelling | Labelling | Labelling | Specific Conc. Limits, M-factors and ATE | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| Index No | Chemical Name | EC No | CAS No | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | Specific Conc. Limits, M-factors and ATE | Notes |
| ‘005-022-00-4 | perboric acid, sodium salt [1] perboric acid, sodium salt, monohydrate [2] perboric acid (HBO(O2)), sodium salt, monohydrate [3] sodium peroxoborate [4] sodium perborate [5] | 234-390-0 [1] 234-390-0 [2] - [3] - [4] 239-172-9 [5] | 11138-47-9 [1] 12040-72-1 [2] 10332-33-9 [3] - [4] 15120-21-5 [5] | Ox. Sol. 3 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H272 H360FD H331 H302 H335 H318 | GHS03 GHS08 GHS06 GHS05 Dgr | H272 H360FD H331 H302 H335 H318 | inhalation: ATE = 0,75 mg/L (dusts or mists) oral: ATE = 890 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | 11’ | |
| ‘005-023-00-X | perboric acid (H3BO2(O2)), monosodium salt trihydrate [1] perboric acid, sodium salt, tetrahydrate [2] perboric acid (HBO(O2)), sodium salt, tetrahydrate [3] sodium peroxoborate, hexahydrate [4] | 239-172-9 [1] 234-390-0 [2] - [3] - [4] | 13517-20-9 [1] 37244-98-7 [2] 10486-00-7 [3] - [4] | Repr. 1B Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H360FD H332 H335 H318 | GHS08 GHS05 GHS07 Dgr | H360FD H332 H335 H318 | inhalation: ATE = 1,2 mg/L (dusts or mists) Eye Dam. 1; H318: C ≥ 36 % Eye Irrit. 2; H319: 22 % ≤ C < 36 % | 11’ | |
| ‘005-024-00-5 | sodium peroxometaborate | 231-556-4 | 7632-04-4 | Ox. Sol. 2 Repr. 1B Acute Tox. 3 Acute Tox. 4 STOT SE 3 Eye Dam. 1 | H272 H360FD H331 H302 H335 H318 | GHS03 GHS08 GHS06 GHS05 Dgr | H272 H360FD H331 H302 H335 H318 | inhalation: ATE = 0,62 mg/L (dusts or mists) oral: ATE = 730 mg/kg bw Eye Dam. 1; H318: C ≥ 22 % Eye Irrit. 2; H319: 14 % ≤ C < 22 % | 11’ | |
| ‘006-104-00-2 | multi-walled carbon tubes (synthetic graphite in tubular shape) with a geometric tube diameter range ≥ 30 nm to < 3 μm and a length ≥ 5 μm and aspect ratio > 3:1, including multi-walled carbon nanotubes, MWC(N)T | — | — | Carc. 1B STOT RE 1 | H350i H372 (lung)(inhalation) | GHS08 Dgr | H350i H372 (lung)(inhalation) | STOT RE 1; H372: C ≥ 1 %; STOT RE 2; H373: 0,1 % ≤ C < 1 %’ | ||
| ‘029-026-00-0 | copper [specific surface area > 0,67 mm2/mg] | 231-159-6 | 7440-50-8 | Aquatic Acute 1 Aquatic Chronic 1 | H400 H410 | GHS09 Wng | H410 | M = 10 M = 1’ | ||
| ‘047-004-00-9 | silver massive: [particle diameter ≥ 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 | H361f H373 (nervous system) | GHS08 Wng | H361f H373 (nervous system)’ | |||
| ‘047-005-00-4 | silver powder: [particle diameter > 100 nm < 1 mm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361f H373 (nervous system) H400 H410 | GHS08 GHS09 Wng | H361f H373 (nervous system) H410 | M = 10 M = 10’ | ||
| ‘047-006-00-X | silver nano: [particle diameter > 1 nm ≤ 100 nm] | 231-131-3 | 7440-22-4 | Repr. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 | H361f H373 (nervous system) H400 H410 | GHS08 GHS09 Wng | H361f H373 (nervous system) H410 | M = 1 000 M = 1 000 ’ | ||
| ‘603-247-00-8 | reaction mass of 1,3-dioxan-5-ol and 1,3-dioxolan-4-ylmethanol | — | — | Repr. 1B | H360Df | GHS08 Dgr | H360Df’ | |||
| ‘605-042-00-9 | α-methyl-1,3-benzodioxole-5-propionaldehyde [1] (S)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2S)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [2] (R)-α-methyl-1,3-benzodioxole-5-propionaldehyde; (2R)-3-(1,3-benzodioxol-5-yl)-2-methylpropanal [3] | 214-881-6 [1] - [2] - [3] | 1205-17-0 [1] 737776-68-0 [2] 737776-59-9 [3] | Skin Sens. 1B | H317 | GHS07 Wng | H317’ | |||
| ‘605-043-00-4 | 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [1] (1α,2α,5α)-2,5-dimethylcyclohex-3-ene-1-carbaldehyde [2] 2,6-dimethylcyclohex-3-ene-1-carbaldehyde [3] 3,5-dimethylcyclohex-3-ene-1-carbaldehyde [4] 3,6-dimethylcyclohex-3-ene-1-carbaldehyde [5] 4,6-dimethylcyclohex-3-ene-1-carbaldehyde [6] reaction mass of 3,5-dimethylcyclohex-3-ene-1-carbaldehyde and 2,4-dimethylcyclohex-3-ene-1-carbaldehyde [7] dimethylcyclohex-3-ene-1-carbaldehyde [8] Dimethylcyclohex-3-ene-1-carbaldehyde [9] 1,2,4(or 1,3,5)-trimethylcyclohex-3-ene-1-carbaldehyde [10] 1,3,4-trimethylcyclohex-3-ene-1-carbaldehyde [11] 2,2,4-trimethylcyclohex-3-ene-1-carbaldehyde [12] 2,4,6-trimethylcyclohex-3-enecarbaldehyde [13] isocyclocitral [14] 3,5,6-trimethylcyclohex-3-ene-1-carbaldehyde [15] 4,6,6-trimethylcyclohex-3-ene-1-carbaldehyde [16] | 268-264-1 [1] 252-395-6 [2] - [3] 268-263-6 [4] 267-186-5 [5] 253-139-6 [6] - [7] 248-742-6 [8] 272-113-5 [9] 276-055-1 [10] - [11] - [12] 215-833-7 [13] 215-638-7 [14] 266-810-3 [15] - [16] | 68039-49-6 [1] 35145-02-9 [2] 6975-94-6 [3] 68039-48-5 [4] 67801-65-4 [5] 36635-35-5 [6] - [7] 27939-60-2 [8] 68737-61-1 [9] 71832-78-5 [10] 40702-26-9 [11] 1726-47-2 [12] 1423-46-7 [13] 1335-66-6 [14] 67634-07-5 [15] 6754-27-4 [16] | Skin Sens. 1 | H317 | GHS07 Wng | H317’ | |||
| ‘606-156-00-1 | acetone oxime | 204-820-1 | 127-06-0 | Carc. 1B Acute Tox. 4 STOT SE 3 STOT RE 2 Eye Dam. 1 Skin Sens. 1 | H350 H312 H336 H373 (blood system) H318 H317 | GHS08 GHS07 GHS05 Dgr | H350 H312 H336 H373 (blood system) H318 H317 | dermal: ATE = 1 100 mg/kg bw’ | ||
| ‘606-157-00-7 | (3E)-dec-3-en-2-one | — | 18402-84-1 | Acute Tox. 4 Asp. Tox. 1 Skin Irrit. 2 Aquatic Chronic 2 | H332 H304 H315 H411 | GHS07 GHS08 GHS09 Dgr | H332 H304 H315 H411 | EUH071 | inhalation: ATE = 1,5 mg/L (dusts or mists)’ | |
| ‘606-158-00-2 | 2-(dimethylamino)-2-[(4-methylphenyl)methyl]-1-[4-(morpholin-4-yl)phenyl]butan-1-one | 438-340-0 | 119344-86-4 | Repr. 1B Aquatic Acute 1 Aquatic Chronic 1 | H360Df H400 H410 | GHS08 GHS09 Dgr | H360Df H410 | M = 1 M = 1’ | ||
| ‘607-770-00-2 | 2,3-epoxypropyl neodecanoate | 247-979-2 | 26761-45-5 | Muta. 2 Skin Sens. 1A | H341 H317 | GHS08 GHS07 Wng | H341 H317 | Skin Sens. 1A; H317: C ≥ 0,001 %’ | ||
| ‘607-771-00-8 | benthiavalicarb-isopropyl (ISO); isopropyl [(S)-1-{[(R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]carbamoyl}-2-methylpropyl]carbamate | — | 177406-68-7 | Carc. 1B Repr. 2 Skin Sens. 1 Aquatic Chronic 2 | H350 H361fd H317 H411 | GHS08 GHS07 GHS09 Dgr | H350 H361fd H317 H411’ | |||
| ‘607-772-00-3 | hexyl salicylate | 228-408-6 | 6259-76-3 | Repr. 2 Skin Sens. 1 | H361d H317 | GHS08 GHS07 Wng | H361d H317’ | |||
| ‘607-773-00-9 | 7-oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | 219-207-4 | 2386-87-0 | Muta. 2 STOT RE 2 Skin Sens. 1 | H341 H373 (nasal cavity) H317 | GHS08 GHS07 Wng | H341 H373 (nasal cavity) H317’ | |||
| ‘607-774-00-4 | tetrasodium 4-amino-5-hydroxy-3,6-bis[[4-[[2-(sulphonatooxy)ethyl]sulphonyl]phenyl]azo]naphthalene-2,7-disulphonate [1] Reaction products of 4-amino-5-hydroxynaphthalene-2,7-disulfonic acid, coupled twice with diazotized 2-[(4-aminophenyl)sulfonyl]ethyl hydrogen sulfate, sodium salts [2] disodium 4-amino-5-hydroxy-3,6-bis{[4-(vinylsulfonyl) phenyl]diazenyl}naphthalene-2,7-disulfonate [3] | 241-164-5 [1] - [2] - [3] | 17095-24-8 [1] - [2] 100556-82-9 [3] | Resp. Sens. 1A Skin Sens. 1 | H334 H317 | GHS08 Dgr | H334 H317’ | |||
| ‘607-775-00-X | Sodium 3-(allyloxy)-2-hydroxypropanesulphonate | 258-004-5 | 52556-42-0 | Repr. 1B Eye Dam. 1 | H360F H318 | GHS08 GHS05 Dgr | H360F H318’ | |||
| ‘609-074-00-4 | 1,4-dichloro-2-nitrobenzene | 201-923-3 | 89-61-2 | Carc. 1B | H350 | GHS08 Dgr | H350’ | |||
| ‘611-182-00-1 | 2-[ethyl[3-methyl-4-[(5-nitrothiazol-2-yl)azo]phenyl]amino]ethanol | 271-183-4 | 68516-81-4 | Skin Sens. 1A | H317 | GHS07 Wng | H317 | Skin Sens. 1A; H317: C ≥ 0,001 %’ | ||
| ‘612-299-00-0 | fenpropidin (ISO); (R,S)-1-[3-(4-tert-butylphenyl)-2-methylpropyl]piperidine | — | 67306-00-7 | Repr. 2 Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 STOT RE 2 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H400 H410 | GHS08 GHS07 GHS05 GHS09 Dgr | H361d H332 H302 H335 H336 H373 (nervous system, eyes, lungs) H315 H318 H317 H410 | Inhalation: ATE = 1,2 mg/L (dusts or mists) oral: ATE = 1 330 mg/kg bw M = 1 000 M = 10 000 ’ | ||
| ‘613-350-00-X | 1H-benzotriazole | 202-394-1 | 95-14-7 | Aquatic Chronic 2 | H411 | GHS09 Wng | H411’ | |||
| ‘613-351-00-5 | methyl-1H-benzotriazole | 249-596-6 | 29385-43-1 | Aquatic Chronic 2 | H411 | GHS09 Wng | H411’ | |||
| ‘616-243-00-6 | N,N'-methylenediacrylamide | 203-750-9 | 110-26-9 | Muta. 1B | H340 | GHS08 Dgr | H340’ | |||
| ‘617-024-00-8 | tert-butyl 2-ethylperoxyhexanoate | 221-110-7 | 3006-82-4 | Repr. 1B Skin Sens. 1 | H360FD H317 | GHS08 GHS07 Dgr | H360FD H317’ |
- (2) the entries corresponding to index numbers 005-005-00-1, 016-022-00-9, 016-094-00-1, 029-019-01-X, 601-037-00-0, 604-020-00-6, 605-001-00-5, 607-001-00-0, 607-043-00-X, 607-094-00-8, 607-198-00-3, 607-315-00-8, 607-432-00-4, 613-272-00-6, 616-127-00-5 and 617-008-00-0 are replaced by the following entries respectively:
| Index No | Chemical Name | EC No | CAS No | Classification | Classification | Labelling | Labelling | Labelling | Specific Conc. Limits, M-factors and ATE | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| Index No | Chemical Name | EC No | CAS No | Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s) | Specific Conc. Limits, M-factors and ATE | Notes |
| ‘005-005-00-1 | trimethyl borate | 204-468-9 | 121-43-7 | Flam. Liq. 3 Repr. 1B Acute Tox. 4* | H226 H360FD H312 | GHS02 GHS08 GHS07 Dgr | H226 H360FD H312 | 11’ | ||
| ‘016-022-00-9 | ethanethiol; ethyl mercaptan | 200-837-3 | 75-08-1 | Flam. Liq. 1 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 | H224 H331 H302 H400 H410 | GHS02 GHS06 GHS09 Dgr | H224 H331 H302 H410 | inhalation: ATE = 7,1 mg/L (vapours) oral: ATE = 680 mg/kg bw’ | ||
| ‘016-094-00-1 | sulfur | 231-722-6 | 7704-34-9 | Skin Irrit. 2 | H315 | GHS07 Wng | H315’ | |||
| ‘029-019-01-X | copper flakes (coated with aliphatic acid) | Acute Tox. 3 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H331 H302 H319 H400 H410 | GHS06 GHS09 Dgr | H331 H302 H319 H410 | inhalation: ATE = 0,733 mg/l (dusts or mists) oral: ATE = 500 mg/kg bw M = 10 M = 1’ | ||||
| ‘601-037-00-0 | n-hexane | 203-777-6 | 110-54-3 | Flam. Liq. 2 Repr. 2 Asp. Tox. 1 STOT SE 3 STOT RE 1 Skin Irrit. 2 Aquatic Chronic 2 | H225 H361f*** H304 H336 H372 (nervous system) H315 H411 | GHS02 GHS08 GHS07 GHS09 Dgr | H225 H361f*** H304 H336 H372 (nervous system) H315 H411’ | |||
| ‘604-020-00-6 | biphenyl-2-ol; 2-phenylphenol; 2-hydroxybiphenyl | 201-993-5 | 90-43-7 | Carc. 2 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 | H351 H314 H318 H317 H400 H410 | GHS08 GHS05 GHS07 GHS09 Dgr | H351 H314 H317 H410 | M = 1 M = 1’ | ||
| ‘605-001-00-5 | formaldehyde … % | 200-001-8 | 50-00-0 | Carc. 1B Muta. 2 Acute Tox. 2 Acute Tox. 4 Skin Corr. 1B Skin Sens. 1A | H350 H341 H330 H302 H314 H317 | GHS08 GHS06 GHS05 Dgr | H350 H341 H330 H302 H314 H317 | EUH071 | inhalation: ATE = 100 ppmV (gases) oral: ATE = 500 mg/kg bw STOT SE 3; H335: C ≥ 5 % Skin Corr. 1B; H314: C ≥ 25 % Skin Irrit. 2; H315: 5 % ≤ C < 25 % Eye Irrit. 2; H319: 5 % ≤ C < 25 % | B, D, F’ |
| ‘607-001-00-0 | formic acid … % | 200-579-1 | 64-18-6 | Flam. Liq. 3 Met. Corr. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1 | H226 H290 H331 H302 H314 H318 | GHS02 GHS05 GHS06 Dgr | H226 H290 H331 H302 H314 | EUH071 | inhalation: ATE = 7,4 mg/L (vapours) oral: ATE = 500 mg/kg bw Flam. Liq. 3; H226: C > 85 % Skin Corr. 1A; H314: C ≥ 90 % Skin Corr. 1B; 314: 10 % ≤ C < 90 % Skin Irrit. 2; H315: 2 % ≤ C < 10 % Eye Dam. 1; H318: C ≥ 10 % Eye Irrit. 2; H319: 2 % ≤ C < 10 % | B’ |
| ‘607-043-00-X | dicamba (ISO); 2,5-dichloro-6-methoxybenzoic acid; 3,6-dichloro-2-methoxybenzoic acid | 217-635-6 | 1918-00-9 | Acute Tox. 4 Acute Tox. 4 STOT SE 3 STOT SE 3 Eye Dam. 1 Aquatic Acute 1 Aquatic Chronic 2 | H332 H302 H335 H336 H318 H400 H411 | GHS07 GHS05 GHS09 Dgr | H332 H302 H335 H336 H318 H410 | inhalation: ATE = 4,0 mg/L (dusts or mists) oral: ATE = 1 500 mg/kg bw M = 1’ | ||
| ‘607-094-00-8 | peracetic acid … % | 201-186-8 | 79-21-0 | Org. Perox. D Acute Tox. 2 Acute Tox. 2 Acute Tox. 3 Skin Corr. 1A Aquatic Acute 1 Aquatic Chronic 1 | H242 H330 H310 H301 H314 H400 H410 | GHS02 GHS06 GHS05 GHS09 Dgr | H242 H330 H310 H301 H314 H410 | EUH071 | inhalation: ATE = 0,2 mg/L (dusts or mists) dermal: ATE = 60 mg/kg bw oral: ATE = 80 mg/kg bw STOT SE 3; H335: C ≥ 1 % M = 10 M = 100 | B, D, T’ |
| ‘607-198-00-3 | propyl 3,4,5-trihydroxybenzoate | 204-498-2 | 121-79-9 | Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H302 H317 H400 H410 | GHS07 GHS09 Wng | H302 H317 H410 | oral: ATE = 1 700 mg/kg bw M = 1 M = 1’ | ||
| ‘607-315-00-8 | glyphosate (ISO); N-(phosphonomethyl)glycine | 213-997-4 | 1071-83-6 | Eye Dam. 1 Aquatic Chronic 2 | H318 H411 | GHS05 GHS09 Dgr | H318 H411’ | |||
| ‘607-432-00-4 | S-metolachlor (ISO); 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide; (R a S a)-2-chloro-N-(6-ethyl-o-tolyl)-N-[(1S)-2-methoxy-1-methylethyl]acetamide [contains 80-100 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide and 0-20 % 2-chloro-N-(2-ethyl-6-methylphenyl)-N-[(2R)-1-methoxypropan-2-yl]acetamide] | — | 87392-12-9 | Carc. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H351 H317 H400 H410 | GHS08 GHS07 GHS09 Wng | H351 H317 H410 | EUH066 | M = 10 M = 10’ | |
| ‘613-272-00-6 | pyraclostrobin (ISO); methyl N-(2-{[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxymethyl}phenyl) N-methoxy carbamate | — | 175013-18-0 | Repr. 2 Acute Tox. 3 Acute Tox. 4 STOT SE 3 STOT RE 2 Skin Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 | H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H400 H410 | GHS08 GHS06 GHS09 Dgr | H361d H331 H302 H335 H373 (liver, gastrointestinal tract, nasal cavity) H315 H410 | inhalation: ATE = 0,58 mg/L (dusts or mists) oral: ATE = 450 mg/kg bw M = 100 M = 100’ | ||
| ‘616-127-00-5 | reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide and N,N'-ethane-1,2-diylbis(12-hydroxyoctadecanamide) [1] reaction mass of N,N'-ethane-1,2-diylbis(decanamide) and 12-hydroxy-N-[2-[(1-oxodecyl)amino]ethyl]octadecanamide [2] | 430-050-2 [1] - [2] | - [1] - [2] | Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H317 H400 H410 | GHS07 GHS09 Wng | H317 H410 | M = 100 M = 10’ | ||
| ‘617-008-00-0 | dibenzoyl peroxide; benzoyl peroxide | 202-327-6 | 94-36-0 | Org. Perox. B Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 | H241 H319 H317 H400 H410 | GHS01 GHS02 GHS07 GHS09 Dgr | H241 H319 H317 H410 | M = 10 M = 10’ |
- (3) the entries corresponding to index numbers 005-017-00-7, 005-017-01-4, 005-018-00-2, 005-018-01-X, 005-019-00-8, 005-019-01-5 and 029-024-00-X are deleted.
ELI: http://data.europa.eu/eli/reg_del/2024/2564/oj
ISSN 1977-0677 (electronic edition)
Reading this document does not replace reading the official text published in the Official Journal of the European Union. We assume no responsibility for any inaccuracies arising from the conversion of the original to this format.
This text is published under EUR-Lex's own terms of reuse, not a Legalize or public-domain licence.
EUR-Lex
Creative Commons Attribution 4.0 International (CC BY 4.0)
© European Union, https://eur-lex.europa.eu — Source: EUR-Lex (Publications Office of the European Union). Reused under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Only EU legislation published in the printed Official Journal of the European Union is deemed authentic; consolidated texts are reproduced here for documentation purposes and have been reformatted to Markdown.